Immatics N.V. (IMTX) Stock Analysis
A live, multi-source view of Immatics N.V. (IMTX): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Immatics N.V.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial.
Sector: Healthcare · Industry: Biotechnology · Germany · 704 employees · immatics.com
Key statistics · as of 2026-09-06
As of 2026-09-06, Immatics N.V. (IMTX) had a market capitalization of $1.46B (forward -4.6) and a beta of 1.33; the shares traded in a 52-week range of $5.67 – $12.41 (64.5% over the year).
- Market cap
- $1.46B
- Enterprise value
- $928.0M
- Forward P/E
- -4.6
- Price / book
- 2.82
- EPS (trailing)
- $-1.84
- EPS (forward)
- $-2.07
- Payout ratio
- 0.0%
- 52-week range
- $5.67 – $12.41
- 52-week change
- 64.5%
- Beta
- 1.33
- Average volume
- 466,447
- Shares outstanding
- 152.2M
- Short % of float
- 5.22%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-10
In RapidTradeView’s 2026-09-10 scan of the US universe, Immatics N.V. (IMTX) last closed at $9.11 (the last completed close before that scan).
Technicals at the scan: RSI 45 (neutral territory), price -2.0% versus its 20-day average, 20-day versus 50-day average spread -1.1%, MACD histogram 0.01.
Sentiment inputs: analyst consensus score 75/100.
Next scheduled company event: in 68 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of IMTX; corporate insiders filed 1 buy and 0 sells (1 filer, latest disclosure 2026-08-27). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Perceptive Advisors Llc (1B/0S). Who is trading what
RapidTradeView pick record
IMTX has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Immatics N.V. (IMTX) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell IMTX.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.